Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Oracle Corporation (ORCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Oracle Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Oracle Corporation trades at $140.9 (market cap $405.11B). The key difference: Oracle Corporation is far larger — about 10.2× Alnylam Pharmaceuticals, Inc.'s market cap, and Oracle Corporation pays a 1.42% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | ORCL | |
|---|---|---|
Market Cap | $39.89B | $405.11B |
Sector | Health | Technology |
52-Week High | $491.22 | $328.33 |
52-Week Low | $278.09 | $136.39 |
Enterprise Value | $38.15B | $534.36B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Oracle (ORCL) trades at $140.68, down 2.49% on the day, with a bearish technical signal but strong fundamental performance. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $2.11 exceeding the $1.96 estimate. Revenue grew to $57.40 billion in 2025, and net income margin improved to 21.67%. The stock faces near-term pressure from AI infrastructure spending concerns, but analyst consensus remains bullish with a $259 price target.
Outlook: Oracle's AI partnerships and cloud growth present long-term upside, though high debt and competitive pressures pose risks. The stock offers value if execution continues, but volatility may persist around earnings. Investors should weigh strong profitability against technical weakness and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
